Management and Outcomes for Neovascular Age-Related Macular Degeneration
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 127 (9) , 1179-1188
Abstract
No abstract availableKeywords
Funding Information
- Allergan
This publication has 58 references indexed in Scilit:
- Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programmeBritish Journal of Ophthalmology, 2013
- Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-upBMC Ophthalmology, 2013
- CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICERetina, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in GermanyActa Ophthalmologica, 2012
- Preferred therapies for neovascular age-related macular degenerationCurrent Opinion in Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDEDRetina, 2011
- Age-Related Macular DegenerationNew England Journal of Medicine, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006